Logo

A Friendly Ghostwritten Paper for Paxil

Aug 21, 2009

Merck and Wyeth weren't the only ones. The Associated Press reports that GlaxoSmithKline had a ghostwriting program to support its antidepressant, Paxil. The program, called CASSPER, instructed salespeople to approach physicians and help them write and publish positive articles about the antidepressant. Los Angeles law firm Baum Hedlund is suing GSK and says they downplayed the risks of the drug. GSK says the program was discontinued many years ago.

Breaking News
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.